Revolutionary Cancer Vaccine Breakthrough at Yale University: 9 Patients Cured
A groundbreaking cancer vaccine developed at Yale University is showing extraordinary promise, offering a potential cure for kidney cancer! In a remarkable Phase 2 trial, the vaccine has achieved complete remission in 9 patients, sparking hope for personalized cancer treatments. This immune-boosting breakthrough could change the future of cancer care forever. Read on to discover how this cutting-edge treatment is redefining the fight against cancer!
A groundbreaking step in cancer treatment has been taken by Yale University: A potential hope for kidney cancer!
A vaccine applied between 2019 and 2021 by scientists targets cancer cells without damaging healthy tissues. Developed by the Yale Cancer Center and the Dana-Farber Cancer Institute, the vaccine is personalized. The success achieved after three years of follow-up is promising.
The vaccine, currently in Phase 2 trials, is customized for each individual.
The vaccine, designed based on the patient's biological features, recognizes and starts destroying tumor-specific mutations through the immune system. As a result, the patient's healthy tissues remain unaffected. Dr. David Braun, the lead author of the study, says, 'Our goal was to directly direct the immune system to cancer cells.'
Based on the fact that every cancer case is unique, scientists focus on stage 3 and 4 clear cell renal cell carcinoma (ccRCC), one of the most dangerous types of kidney cancer.
In a group of 9 patients who were followed for three years after receiving the vaccine, improvements were observed. More importantly, the recurrence of cancer, known to occur in 20-50% of cancer patients, did not appear in these patients.
The data obtained shows that the immune system recognizes and responds to 65% of mutations!
The Phase 1 vaccine is undergoing Phase 2 trials, with safety being tested. Of the 7 doses administered to 9 patients, 5 were for the initial phase, and 2 were for booster doses. In the vaccine treatment used to eliminate remaining tumors after surgery, 4 patients received only the vaccine, while 5 patients also received a low dose of the immune therapy drug ipilimumab.
Additionally, the vaccine does not cause severe side effects: mild flu-like symptoms were observed.
Dr. Braun, the lead author, says, 'Seeing a strong and long-lasting response from the immune system through T-cells is extremely encouraging. This is a sign that we may be able to make the immune response permanent in the fight against cancer.' The fact that the patients experienced only mild flu-like symptoms suggests it is possible to avoid severe side effects.
This promising research conducted by Yale University scientists is revolutionary for one of the most common cancer types worldwide.
Over 400,000 new cases are detected each year globally, and the personalized cancer vaccine may break new ground. However, further Phase 2 trials and their results are needed to confirm this.
Keşfet ile ziyaret ettiğin tüm kategorileri tek akışta gör!
Test
Gündem
Magazin
Video
Send Comment